Improving healthcare through quality research!



Hereditary Angioedema / HAE Trials



Clinical Research Associates of Tidewater located in Norfolk, Virginia is conducting two clinical trials for individuals with Hereditary Angioedema (HAE).

Clinical Research Associates of Tidewater has been conducting phase II IV clinical trials since 1983. The Medical Director, Dr. Duane Wombolt, is board certified in internal medicine. Conveniently located in the Norfolk Medical Tower, Clinical Research Associates of Tidewater is accessible to all cities and outlying counties in the Hampton Roads area.

Individuals participating in Hereditary Angioedema / HAE trials live in Richmond, Williamsburg, Newport News, Hampton, Suffolk, Norfolk, Portsmouth, Chesapeake, Virginia Beach, the Eastern Shore of Virginia as well as Northeastern North Carolina.


Hereditary Angioedema (HAE)
Background

Hereditary Angioedema (HAE) is a rare inherited disorder characterized by recurrent and self-limiting episodes of edema (swelling) of the skin, larynx (voice box), and gastrointestinal tract. There are two separate types of HAE (Type I and Type II). Depending on type, individuals have either mutant forms or low functional serum (blood) concentration of C1 esterase inhibitor (C1-INH). Frequency of attacks varies among individuals and is not uniform within families. HAE attacks generally last 1-4 days. Therapies for HAE in the United States are currently limited. Medical management of HAE involves treatment of symptoms in acute attacks and maintenance therapy. Maintenance therapy consists of treatment with androgens (steroids that acts as a male sex hormone). However, their use is accompanied by significant side effects and long term safety has not been assessed.

Current Hereditary Angioedema (HAE) Clinical Trials

Both clinical trials are designed to treat individuals experiencing an acute attack of HAE.

Icatibant HAE Trial

Icatibant was developed by Aventis AG and has been licensed to Jerini AG for the indication of HAE. Icatibant is a bradykinin receptor agonist (inhibits inflammation). Inflammation at the cell level contributes to acute attacks of HAE.

To participate in this study one must have either Type I or Type II HAE, be at least 18 years of age and must be experiencing an acute attack of HAE.

DX-88 HAE Trial

DX-88 was developed by Dyax-Genzyme LLC. DX-88 is a protein that inhibits the first stages of inflammation also associated with acute attacks of HAE.

To participate in this study one must have either Type I or Type II HAE, be at least 10 years of age, and must be experiencing an acute attack of HAE.

Financial compensation may be available for time and travel in both trials and an office screening visit is required prior to acute treatment.

For More Information and to Contact Us:

Please visit us on the web at www.crat.org or call us at 757-627-7446.

 

 
 

Visitor Number
Hit Counter
 
Hosted by Prosmartwebs